Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
- Rastogi, P.
- O'shaughnessy, J.
- Martin, M.
- Boyle, F.
- Cortes, J.
- Rugo, H.S.
- Goetz, M.P.
- Hamilton, E.P.
- Huang, C.-S.
- Senkus, E.
- Tryakin, A.
- Cicin, I.
- Testa, L.
- Neven, P.
- Huober, J.
- Shao, Z.
- Wei, R.
- André, V.
- Munoz, M.
- San Antonio, B.
- Shahir, A.
- Harbeck, N.
- Johnston, S.
ISSN: 1527-7755, 0732-183X
Year of publication: 2024
Volume: 42
Issue: 9
Pages: 987-993
Type: Article